Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Based on technology from SkylineDx, the test aims to aid treatment decisions for patients with the deadliest form of skin cancer
Patients classified as low-risk by MelaNodal Predict are shown to have survival rate of over 90 percent
Posted In: DGX